$20m Takeda-ImmunoGen licensing deal for cancer ADCs

By Fiona BARRY contact

- Last updated on GMT

Takeda will pay $20m, plus milestone payments and royalties, to ImmunoGen. (Image: Incase)
Takeda will pay $20m, plus milestone payments and royalties, to ImmunoGen. (Image: Incase)

Related tags: Immune system

Takeda has licensed technology from ImmunoGen to make two antibody drug conjugates (ADCs) targeting cancer.

ADCs are made of a monoclonal antibody attached to a cancer-killing “payload” which binds to a target on cancer cells. 

Under the terms of the deal, ImmunoGen will license its DNA-acting highly potent cytotoxic payloads, known as IGNs. These allow drugmakers to target some types of cancer which would not otherwise be treatable with ADCs, such as those insensitive to tubulin-acting agents or with less robust target expression.

Takeda’s two cancer targets are unknown. The Japanese company will pay ImmunoGen $20m (€18m) upfront, plus milestone payments up to $210m (€192m). It has the option to take a licence for a third target for an extra fee.

Immunogen stock jumped 18% from a low of $7.43 before markets opened on Monday, closing at $8.45 on Tuesday. The company said it will not update its financial guidance for 2015. 

Antibody drug conjugates

ImmunoGen’s payload agents include tubulin-acting maytansinoids, currently used in several marketed ADCs, including Genentech’s Kadcyla.

As well as payloads, the company’s ADC technology portfolio includes engineered linkers which attach agents to their target. These are designed to be stable while the ADC is traveling through the blood stream to the cancer cells, before helping the payload release.

ADC technology is a critically important tool in addressing unmet needs in oncology​,” said Christopher Claiborne, head of oncology drug discovery at Takeda. “By partnering with ImmunoGen, we are able to leverage this important technology in Takeda’s R&D program and bring novel agents through the clinic​.”  

ImmunoGen has also licensed its ADC technology to Novartis​ and Eli Lilly.

The latest deal was made through Takeda’s subsidiary Millennium Pharmaceuticals.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars